| [1] |
Hopper T, Olabisi OA. APOL1-mediated kidney disease [J]. JAMA, 2024, 331(19): 1668-1669.
|
| [2] |
Peng T, Chang D, Chen T, et al. A novel APOL1 membrane-addressing domain mutation (p.T272I) in Chinese twins with FSGS: implications for podocyte injury and ion channel disruption [J]. Ren Fail, 2025, 47(1): 2553384.
|
| [3] |
Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications [J]. Clin J Am Soc Nephrol, 2021, 16(2): 294-303.
|
| [4] |
Daneshpajouhnejad P, Kopp JB, Winkler CA, et al. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning [J]. Nat Rev Nephrol, 2022, 18(5): 307-320.
|
| [5] |
Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic AOPL1 variants with kidney disease in African Americans [J]. Science, 2010, 329(5993): 841-845.
|
| [6] |
Narjoz C, Tran Julie VHL, Rabant M, et al. Diagnostic yield of APOL1 p．N264K variant screening in daily practice [J]. Kidney Int Rep, 2024, 9(6): 1916-1918.
|
| [7] |
Okamoto K, Rausch JW, Wakashin H, et al. APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R [J]. Commun Biol, 2018, 1: 188.
|
| [8] |
Giovinazzo JA, Thomson RP, Khalizova N, et al. Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity [J]. Elife, 2020, 9: e51185.
|
| [9] |
Allison SJ. Toxicity of APOL1 channel activity [J]. Nat Rev Nephrol, 2020, 16(8): 430.
|
| [10] |
Beckerman P, Susztak K. APOL1: the balance imposed by infection, selection, and kidney disease [J]. Trends Mol Med, 2018, 24(8): 682-695.
|
| [11] |
Kumar V, Paliwal N, Ayasolla K, et al. Disruption of APOL1-miR193a axis induces disorganization of podocyte actin cytoskeleton [J]. Sci Rep, 2019, 9(1): 3582.
|
| [12] |
Wu J, Raman A, Coffey NJ, et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy [J]. J Clin Invest, 2021, 131(20): e136329.
|
| [13] |
Ekulu PM, Nkoy AB, Adebayo OC, et al. A focus on the association of APOL1 with kidney disease in children [J]. Pediatr Nephrol, 2021, 36(4): 777-788.
|
| [14] |
Vasquez-Rios G, De Cos M, Campbell KN. Novel therapies in APOL1-mediated kidney disease: from molecular pathways to therapeutic options [J]. Kidney Int Rep, 2023, 8(11): 2226-2234.
|
| [15] |
Gutierrez OM. APOL1 high-risk genotypes and kidney disease risk in middle-aged black adults: more questions than answers [J]. Kidney Med, 2024, 6(6): 100842.
|
| [16] |
Hung AM, Shah SC, Bick AG, et al. APOL1 risk variants, acute kidney injury, and death in participants with African ancestry hospitalized with COVID-19 from the million veteran program [J]. JAMA Intern Med, 2022, 182(4): 386-395.
|
| [17] |
Kopp JB, Winkler CA, Zhao X, et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial [J]. J Am Soc Nephrol, 2015, 26(6): 1443-1448.
|
| [18] |
Pollak MR, Friedman DJ. APOL1-associated kidney disease: modulators of the genotype-phenotype relationship [J]. Curr Opin Nephrol Hypertens, 2025, 34(3): 191-198.
|
| [19] |
Sula Karreci E, Jacas S, Donovan O, et al. Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2 [J]. Kidney Int, 2024, 106(6): 1072-1085.
|
| [20] |
Weitzel KW, Alexander M, Bernhardt BA, et al. The IGNITE network: a model for genomic medicine implementation and research [J]. BMC Med Genomics, 2016, 9: 1.
|
| [21] |
刘俊，陈客宏. 终末期肾脏病患者运动干预的作用研究进展[J/OL]. 中华肾病研究电子杂志，2024, 13(4): 219-225.
|
| [22] |
Lee T, Ma L, Freedman BI. APOL1 testing in clinical practice and opportunities for new therapies [J]. Curr Opin Nephrol Hypertens, 2025, 34(6): 500-506.
|
| [23] |
Soler MJ, Glassock RJ, Fervenza FC. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants [J]. N Engl J Med, 2023, 388(26): 2490.
|
| [24] |
Egbuna O, Audard V, Manos G, et al. Safety and tolerability of the APOL1 inhibitor, inaxaplin, following single- and multiple-ascending doses in healthy adults [J]. Glomerular Dis, 2024, 4(1): 64-73.
|
| [25] |
Yang YW, Poudel B, Frederick J, et al. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice [J]. Mol Ther, 2022, 30(7): 2491-2504.
|
| [26] |
Olabisi OA, Barrett NJ, Lucas A, et al. Design and rationale of the phase 2 baricitinib study in apolipoprotein L1-mediated kidney disease (JUSTICE) [J]. Kidney Int Rep, 2024, 9(9): 2677-2684.
|
| [27] |
Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease [J]. N Engl J Med, 2013, 369(23): 2183-2196.
|
| [28] |
Doshi MD, Ortigosa-Goggins M, Garg AX, et al. APOL1 genotype and renal function of black living donors [J]. J Am Soc Nephrol, 2018, 29(4): 1309-1316.
|